Medeuropa S.R.L.

The Medical Oncology unit at Medeuropa S.R.L. conducts trials targeting neoplastic diseases, with a primary focus on extensive-stage small-cell lung cancer.

• Evaluation of MK-7684A combined with etoposide/platinum chemotherapy
• Comparison with atezolizumab‑based regimen
• Overall survival as primary endpoint
• Multi‑investigator collaboration (4 investigators)

These investigations seek to determine whether novel drug combinations can extend survival for patients with advanced lung cancer.

In the same department, researchers are studying esophageal carcinoma using immunotherapy integrated with definitive chemoradiotherapy.

• Concurrent dCRT plus pembrolizumab versus placebo
• Assessment of event‑free survival and overall survival
• PD‑L1 CPS stratified analysis (≥10, ≥1, all)
• Focus on improving outcomes for locally advanced disease

The aim is to enhance treatment effectiveness and potentially establish a new standard of care for esophageal cancer patients.